A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD

Chest

Volumn 128, Issue 1, 2005, Pages 48-54

  Nair, Suresh ^a   Thomas, Enson ^a   Pearson, Stanley B ^a   Henry, Michael T ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Acute exacerbation; Albuterol; COPD; Dose response; 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 22244493276     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.1.48     Document Type: Article

References (24)

1. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Grit Care Med 2000; 161:1608-1613
2. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir, Grit Care Med 1998; 157:1418-1422
3. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852
4. 2-agonists for stable chronic obstructive pulmonary disease. The Cochrane Library. Oxford, UK: Update Software 2003; Issue 3
5. Belman MJ, Botnick WC, Shin WJ. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:967-975
6. Walters EH, Cockroft A, Griffiths K, et al. Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels. Thorax 1981; 36:625-628
7. Stainforth JN, Lewis RA, Tattersfield AE. Dosage and delivery of nebulised β in hospital. Thorax 1983; 38:751-754
8. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5):S1-S28
9. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease; national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59(suppl 1):1-232
10. Teale C, Pearson SB. Regular nebulised terbutaline in chronic obstructive airways disease: dose-response studies fail to detect tolerance. Br J Clin Pharmacol 1991; 32:111-114
11. Teale C, Morrison JFJ, Page RL, et al. Dose response to inhaled salbutamol in chronic obstructive airways disease. Postgrad Med J 1991; 67:754-756
12. Teale C, Morrison JFJ, Muers MF, et al. Response to nebulised ipratropium bromide and terbutaline in acute severe asthma. Respir Med 1992; 86:215-218
13. American Thoracic Society. ATS standardization of spirometry update. Am J Respir Grit Care Med 1994; 152:1107-1136
14. 2- agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons
15. Lioberes P, Ramis L, Monserrat JM, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1:536-539
16. Johnson M. The β-adrenoreceptor. Am J Respir Grit Care Med 1998; 158:3143-8153
17. Wachsman DE, Kavaler JP, Sugar IP, et al. Kinetic studies of desensitisation and resensitisation of the relaxation response to β-2 adrenoreceptor agonists in isolated guinea pig trachea. J Pharmacol Exp Ther 1997; 280:332-345
18. Gross NJ, Petty TL, Friedman M, et al. Dose response to ipratropium as a nebulised solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139:1188-1191
19. Barnes PJ, Basbaum CB, Nadel JA. Autoradiographic localization of autonomic receptors in airway smooth muscle, marked difference between large and small airways. Am Rev Respir Dis 1983; 127:758-762
20. Cheng JB, Townley RG. Comparison of muscarinic and β-adrenergic receptors between bovine peripheral lung and tracheal smooth muscles: a striking difference in receptor concentration. Life Sci 1982; 30:2079-2086
21. O'Donnell DE, Fokert KA, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001; 18:914-920
22. Britton J, Tattersfield A. Comparison of curaulative and non-cumulative techniques to measure dose-response curves for β agonists in patients with asthma. Thorax 1984; 39:597-599
23. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (Ventstream). Thorax 1994; 49:762-770
24. Lipworth BJ, Clark DJ. Effects of airway caliber on lung delivery of nebulised salbutamol. Thorax 1997; 52:1036-1039